Evidence map›Paper›PMID 38036503›Full record

ArticleNature communications2023

Explainable machine learning for profiling the immunological synapse and functional characterization of therapeutic antibodies.

Sayedali Shetab Boushehri, Katharina Essig, Nikolaos-Kosmas Chlis, Sylvia Herter, Marina Bacac, Fabian J Theis, Elke Glasmacher, Carsten Marr, Fabian Schmich

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sayedali Shetab Boushehri *Institute of AI for Health, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.ORCID 0000-0003-3391-9294
Katharina Essig *Large Molecule Research (LMR), Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany.
Nikolaos-Kosmas ChlisLarge Molecule Research (LMR), Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany.
Sylvia HerterRoche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Zurich, Switzerland.ORCID 0000-0002-2446-696X
Marina BacacRoche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Zurich, Switzerland.
Fabian J TheisInstitute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.ORCID 0000-0002-2419-1943
Elke GlasmacherResearch and Early Development (RED), Roche Diagnostics Solutions, Roche Innovation Center Munich, Munich, Germany. elke.glasmacher@roche.com.ORCID 0000-0003-1265-2543
Carsten MarrInstitute of AI for Health, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. carsten.marr@helmholtz-munich.de.ORCID 0000-0003-2154-4552
Fabian SchmichData & Analytics (D&A), Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany. fabian.schmich@roche.com.ORCID 0000-0003-1604-4406
Roche (Switzerland) · CHHelmholtz Zentrum München · DERoche Pharma AG (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic antibodies are widely used to treat severe diseases. Most of them alter immune cells and act within the immunological synapse; an essential cell-to-cell interaction to direct the humoral immune response. Although many antibody designs are generated and evaluated, a high-throughput tool for systematic antibody characterization and prediction of function is lacking. Here, we introduce the first comprehensive open-source framework, scifAI (single-cell imaging flow cytometry AI), for preprocessing, feature engineering, and explainable, predictive machine learning on imaging flow cytometry (IFC) data. Additionally, we generate the largest publicly available IFC dataset of the human immunological synapse containing over 2.8 million images. Using scifAI, we analyze class frequency and morphological changes under different immune stimulation. T cell cytokine production across multiple donors and therapeutic antibodies is quantitatively predicted in vitro, linking morphological features with function and demonstrating the potential to significantly impact antibody design. scifAI is universally applicable to IFC data. Given its modular architecture, it is straightforward to incorporate into existing workflows and analysis pipelines, e.g., for rapid antibody screening and functional characterization.

Indexed as

Cell CommunicationImmunological SynapsesHumansMachine LearningWorkflow

Identifiers

PMID38036503
PMCPMC10689847
OpenAlexW4389175266

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.